AFN/USD (YPH.MU)
| Previous close | 8.99 |
| Open | 8.99 |
| Bid | 8.95 x 0 |
| Ask | 9.02 x 0 |
| Day's range | 8.99 - 8.99 |
| 52-week range | 8.91 - 15.61 |
| Volume | |
| Avg. volume | 39 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Thomson Reuters StreetEvents
Q4 2023 Taysha Gene Therapies Inc Earnings Call
Q4 2023 Taysha Gene Therapies Inc Earnings Call
- Reuters
US FDA declines to approve Astellas' gastric cancer drug
Japan's Astellas Pharma said on Monday the U.S. Food and Drug Administration (FDA) has declined to approve its experimental drug to treat a type of gastric cancer, citing issues related to a third-party manufacturer. The FDA has not raised any concerns related to the clinical data, and is not requesting additional clinical studies, Astellas said. The company said it is working closely with the FDA and the third-party manufacturer to quickly resolve the regulator's feedback, adding that the decision does not affect any other Astellas product.
- Reuters
UPDATE 2-US FDA approves Astellas' combination therapy for bladder cancer
The U.S. Food and Drug Administration on Friday approved Astellas Pharma's Padcev in combination with Merck's Keytruda for a type of bladder cancer. In April, FDA had granted accelerated approval to this combination for treating patients suffering from the disease that are ineligible for chemotherapy with the commonly used cancer drug, cisplatin. The FDA said on Friday the approval was based on a late-stage trial where the combination therapy met major efficacy outcomes of overall survival and progression-free survival, which is how long a patient lives without the disease getting worse after treatment.
